BMI View: Multinational drugmaker presence in Botswana will be limited to imports as the small market
size and lack of investment incentives deter any large-scale investment plans. Although generic drugs will
retain their dominance in terms of market share, as the bur ..."
BMI View: The growth of Botswana's pharmaceutical and healthcare markets will remain limited over the
coming years as multinational drugmakers are unlikely to establish a direct manufacturing presence within
the country. The government's ongoing commitment to alleviat ..."
BMI View: Botswana's pharmaceutical market will continue to present an unattractive investment
destination for multinational drugmakers. The country will remain extremely reliant on importing its
pharmaceutical needs over our forecast period, as plans to expand local ..."
BMI View: Botswana's pharmaceutical market will remain of little interest to multinational drugmakers. Its
small market size will continue to limit commercial opportunities, and generic drugs will retain their
dominance in terms of market share by both volume and valu ..."
BMI View: Communicable diseases will continue to dominate Botswana's disease profile, with HIV/AIDS
posing the greatest burden. The government's provision of free antiretroviral treatment will provide
opportunities for generic drugmakers within the public healthcare s ..."
BMI View: With Botswana's plans to manufacture drugs locally stalling, the country will remain reliant on
importing its pharmaceutical needs for the foreseeable future. The government's commitment to healthcare
sector development will continue driving import growth to ..."
BMI View: Our outlook for the pharmaceutical and healthcare markets of Botswana is reasonably positive
due to the government's increasing commitment to improve the country's healthcare sector. The country's
import reliance for pharmaceuticals, coupled with the forecast deprecia ..."
BMI View: We remain relatively optimistic over the growth potential of Botswana's pharmaceutical and
healthcare sector, given the government's aim to improve healthcare. However, implementation of these
healthcare aims remain a risk, as issues such as counterfeit phar ..."
BMI View: While Botswana offers a relatively stable environment for pharmaceutical and healthcare
investors, low per-capita pharmaceutical and healthcare expenditure will remain a key downside risk to the
development of the sector. In addition, the overall Sub-Saharan ..."
BMI View: Botswana remains as one of the more advanced countries in the African region in terms of its
provision of healthcare. However, the region as a whole remains impoverished and it is unlikely that we will
see significant foreign investments. Consequently, we maintain our ..."